First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.
Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.
Pembrolizumab monotherapy and pembrolizumab plus chemotherapy prolonged OS in recurrent/metastatic HNSCC.
Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.
A suite of assays that rely on a single instrument and its related software could help researchers identify factors that drive immunotherapy response.
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.
PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.
The TRK inhibitor larotrectinib continues to show efficacy in TRK-fusion cancers, regardless of patient age or cancer type.
First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.
Talazoparib resulted in better patient-reported outcomes compared with chemotherapy among women with TNBC and BRCA mutations in the EMBRACA trial.